Radiotherapy, Cetuximab, and Injections of TNFerade™ Biologic for Elderly or Frail Patients With Head and Neck Cancer

Head and Neck Cancer Clinical Trial

Official title:

A Phase I/II Safety, Tolerability and "Proof of Concept" Study of Radiotherapy, Cetuximab, and Intratumoral Injections of TNFerade™ Biologic (AdGVEGR.TNF.11D) for Elderly or Frail Patients or Intermediate Stage Patients With Head and Neck Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00496236
• Other study ID #: GV-001.010
• Secondary ID: GV-001.010 (TNF-
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: June 28, 2007
• Last updated: February 22, 2012

Study information

• Verified date: May 2011
• Source: GenVec
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This study is looking at the safety and tolerability of TNFeradeä Biologic combined with conventional once daily radiation therapy in elderly or frail patients with new onset locally advanced head and neck tumors.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age 70 or older with an ECOG performance status 0-2,or

• Patients > 18 years of age with ECOG performance status of 2 or greater, or

• Patients > 18 years of age unsuitable for concurrent chemotherapy or surgery due to:

• Renal failure, or

• Severe cardiopulmonary disease, or

• Other end-organ dysfunction that precludes the use of chemotherapy but does not preclude the administration of TNFerade™ Biologic or cetuximab

• Tumor that is unresectable or inoperable and not amenable to regular concurrent chemoradiotherapy

• Patients > 18 years of age with intermediate stage disease, stages II-III (T2-T3, N0-1MO) carcinoma of the head and neck, including oral cavity, pharynx larynx, paranasal sinuses and cervical esophagus. Selected patients with stage IV disease (T4N0-1M0) will also be considered for enrollment. Therapy is given with curative intent.

• Disease should be clinically accessible (measurable or evaluable) to keep injection via direct intratumoral injection

• Informed consent

Exclusion Criteria:

• History of malignancy in the last 2 years except carcinoma in situ of the cervix or bladder, non-melanomatous skin cancer, or localized early stage prostate cancer, with patients continually disease free, or cancers that are not felt to influence treatment for head and neck cancer and life expectancy of patient

• Overt systemic metastatic disease

• Previous radiation or chemotherapy for malignancy of the head and neck

• Clinical evidence of active infection of any type

• pregnant or lactating women

• Experimental medications within the last 4 weeks prior to Day 1

• Chronic treatment for greater than 6 months with steroids at doses above 10 mg/day prednisone (or equivalent)

• Patients receiving hormone replacement therapy or hormonal contraceptives within 2 weeks of day 1

• Patients who have undergone surgery within the last 1 month

• Allergic reaction to cetuximab

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Head and Neck Cancer
• Head and Neck Neoplasms

Intervention

Drug:
• TNFerade biologic

Locations

Country	Name	City	State
United States	University of Chicago	Chicago	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
GenVec

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The maximum tolerated dose established in the Phase I (dose-finding) portion of the study will be used to assess the investigational drug's ability to enhance clinical outcome. The primary endpoint being locoregional control rate at 24 months.
Secondary	Locoregional control at 3,6, and 12 months, objective response rate, progression-free survival at 3,6,12, and 24 months, and the rate of distal metastases at 3,6, 12 and 24 months will also be assessed.